CWY0 logo

Clearmind Medicine DB:CWY0 Stock Report

Last Price

€1.26

Market Cap

€5.1m

7D

-4.5%

1Y

n/a

Updated

04 Nov, 2024

Data

Company Financials

CWY0 Stock Overview

A clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.

CWY0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Clearmind Medicine Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clearmind Medicine
Historical stock prices
Current Share PriceUS$1.26
52 Week HighUS$6.00
52 Week LowUS$0.88
Beta-1.48
11 Month Change16.42%
3 Month Change6.18%
1 Year Changen/a
33 Year Change-99.72%
5 Year Changen/a
Change since IPO-99.78%

Recent News & Updates

Recent updates

Shareholder Returns

CWY0DE PharmaceuticalsDE Market
7D-4.5%-1.8%-1.8%
1Yn/a-12.8%13.6%

Return vs Industry: Insufficient data to determine how CWY0 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CWY0 performed against the German Market.

Price Volatility

Is CWY0's price volatile compared to industry and market?
CWY0 volatility
CWY0 Average Weekly Movement11.0%
Pharmaceuticals Industry Average Movement7.9%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: CWY0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: CWY0's weekly volatility has decreased from 24% to 11% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2017n/aAdi Zuloff-Shaniwww.clearmindmedicine.com

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.

Clearmind Medicine Inc. Fundamentals Summary

How do Clearmind Medicine's earnings and revenue compare to its market cap?
CWY0 fundamental statistics
Market cap€5.06m
Earnings (TTM)-€7.73m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CWY0 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$8.44m
Earnings-US$8.44m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.08
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CWY0 perform over the long term?

See historical performance and comparison